{"id":390236,"date":"2020-04-24T00:00:00","date_gmt":"2020-04-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0017-2020-biopharma-acute-myeloid-leukemia-current-treatment-physician-insights-us-2020\/"},"modified":"2026-04-15T23:23:03","modified_gmt":"2026-04-15T23:23:03","slug":"cutron0017-2020-biopharma-acute-myeloid-leukemia-current-treatment-physician-insights-us-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0017-2020-biopharma-acute-myeloid-leukemia-current-treatment-physician-insights-us-2020\/","title":{"rendered":"Acute Myeloid Leukemia | Current Treatment: Physician Insights | US | 2020"},"content":{"rendered":"<p>Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved four drugs for AML in 2017 (Pfizer\u2019s Mylotarg, Novartis\u2019s Rydapt, Agios\u2019s Idhifa, and Jazz\u2019s Vyxeos) and an additional four drugs in 2018 (Agios\u2019s Tibsovo, AbbVie\u2019s Venclexta, Pfizer\u2019s Daurismo, and Astellas\u2019s Xospata).<\/p>\n<p>In light of impressive data for multiple newly approved drugs in AML subpopulations, the treatment paradigm is changing rapidly by shifting toward increasingly targeted and personalized therapies.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>Following the FDA approval of eight drugs for AML since 2017, how do physicians incorporate these additional therapy options into their practices?<\/li>\n<li>What is the uptake of AbbVie\u2019s Venclexta in patients ineligible for intensive induction? Which Venclexta combinations are prescribed most frequently?<\/li>\n<li>Is Astellas\u2019s Xospata prescribed for <em>FLT3\u00a0<\/em>mutation-positive patients in the relapsed\/refractory setting? How is the drug\u2019s uptake affected by prescribing of other FLT3 inhibitors, including Novartis\u2019s Rydapt\u00a0in the previously untreated setting or Nexavar in the relapsed\/refractory setting?<\/li>\n<li>What will be the uptake of IDH inhibitors in patients with <em>IDH<\/em> mutations?<\/li>\n<\/ul>\n<p><strong>Product description:<\/strong><\/p>\n<p><em>Current Treatment:<\/em> Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered: <\/strong>United States.<\/p>\n<p><strong>Primary research: <\/strong>Survey of ~100 hematologist-oncologists in the United States.<\/p>\n<p><strong>Key drugs covered:<\/strong> Venclexta, Xospata, Idhifa, Tibsovo, Vyxeos, Daurismo, Mylotarg, Rydapt.<\/p>\n","protected":false},"template":"","class_list":["post-390236","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-myeloid-leukemia","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-942"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390236\/revisions"}],"predecessor-version":[{"id":393361,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390236\/revisions\/393361"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}